You are here:Home-Chemical Inhibitors & Agonists-Others-Other Targets-PCC0208017
PCC0208017

Chemical Structure : PCC0208017

CAS No.: 2623158-64-3

PCC0208017 (PCC 0208017, PCC-0208017)

Catalog No.: PC-73077Not For Human Use, Lab Use Only.

PCC0208017 is a potent, selective dual small-molecule inhibitor of MARK3 and MARK4 with IC50 of 1.8 and 2.01 nM, respectively.

Packing Price Stock Quantity
5 mg $258 In stock
10 mg $398 In stock
25 mg $558 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

PCC0208017 is a potent, selective dual small-molecule inhibitor of MARK3 and MARK4 with IC50 of 1.8 and 2.01 nM, respectively.
PCC0208017 displays lower inhibitory activity against MARK1 and MARK2, with IC50 values of 31.4 and 33.7 nM respectively, with no strong inhibitory activity against 18 common oncogenic kinases.
PCC0208017 decreases the phosphorylation of Tau, suppresses the proliferation of glioma cells GL261, U87-MG and U251 cells with IC50 of 2.77, 4.02 and 4.45 uM.
PCC0208017 disrupts microtubule dynamics and induces G2/M phase cell cycle arrest and cell apoptosis, suppresses cell migration and inhibits endothelial tube formation.
PCC0208017 demonstrates robust antitumor activity in vivo and displays good BBB permeability.
Microtubule-affinity regulating kinases (MARKs) are novel mammalian serine/threonine kinases that phosphorylate microtubule associated proteins (MAPs), such as Tau, and regulate cell cycle progression and cytoskeletal dynamics. Four MARK isoforms have been identified in humans (MARK1, MARK2, MARK3 and MARK4) and all are highly enriched in human brain.

Physicochemical Properties

M.Wt 403.413
Formula C19H20F3N7
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N4-((1H-pyrazol-3-yl)methyl)-N2-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine

References

1. Fangfang Li, et al. Acta Pharm Sin B. 2020 Feb;10(2):289-300.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: